Technical Analysis for SNSS - Sunesis Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 0.47 -20.34% -0.12
SNSS closed down 20.34 percent on Friday, January 18, 2019, on 6.59 times normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SNSS trend table...

Date Alert Name Type % Chg
Jan 18 Fell Below 20 DMA Bearish 0.00%
Jan 18 MACD Bearish Centerline Cross Bearish 0.00%
Jan 18 1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Jan 18 Volume Surge Other 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 1,2,3 Pullback Bullish Bullish Swing Setup -20.34%
Jan 17 Wide Bands Range Expansion -20.34%
Jan 16 MACD Bullish Centerline Cross Bullish -30.88%
Jan 16 Inside Day Range Contraction -30.88%
Jan 16 Wide Bands Range Expansion -30.88%

Older signals for SNSS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company's principal product includes Vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It is conducting various clinical trials of Vosaroxin, including a Phase III clinical trial, known as the VALOR trial in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and a Phase II/III trial known as the LI-1 trial in patients older than 60 years with AML or high-risk myelodysplastic syndrome. In addition, the company has completed the Phase II portion of a Phase Ib/II trial of Vosaroxin in combination with cytarabine for the treatment of patients with relapsed or refractory AML; and Phase II trial in previously untreated patients with 60 years of age or older with AML or REVEAL-1 trial, which explored three dosing schedules of vosaroxin. It has a license agreement with Dainippon Sumitomo Pharma Co., Ltd. for the development and commercialization of Vosaroxin; a collaboration agreement with Millennium for the development of pan-Raf kinase inhibitor and one additional undisclosed kinase inhibitor program in oncology; and a collaboration agreement with Biogen Idec, Inc. to discover, develop, and commercialize small molecule inhibitors of a preclinical kinase inhibitor program in immunology. The company formerly known as, Mosaic Pharmaceuticals, Inc., was founded in 1998 and is headquartered in South San Francisco, California.
Is SNSS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 7.69
52 Week Low 0.2
Average Volume 486,271
200-Day Moving Average 1.861
50-Day Moving Average 0.7045
20-Day Moving Average 0.4853
10-Day Moving Average 0.5994
Average True Range 0.1104
ADX 30.06
+DI 27.9381
-DI 23.4597
Chandelier Exit (Long, 3 ATRs ) 0.5088
Chandelier Exit (Short, 3 ATRs ) 0.5312
Upper Bollinger Band 0.7642
Lower Bollinger Band 0.2064
Percent B (%b) 0.47
BandWidth 114.939213
MACD Line -0.0082
MACD Signal Line -0.0398
MACD Histogram 0.0316
Fundamentals Value
Market Cap 11.05 Million
Num Shares 23.5 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -0.25
Price-to-Sales 24.54
Price-to-Book 0.00
PEG Ratio -0.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.58
Resistance 3 (R3) 0.59 0.56 0.56
Resistance 2 (R2) 0.56 0.54 0.56 0.55
Resistance 1 (R1) 0.52 0.52 0.51 0.51 0.55
Pivot Point 0.49 0.49 0.49 0.49 0.49
Support 1 (S1) 0.45 0.47 0.44 0.44 0.39
Support 2 (S2) 0.42 0.45 0.42 0.39
Support 3 (S3) 0.38 0.42 0.38
Support 4 (S4) 0.37